KR100606131B1 - 디뉴클레오티드 및 그의 용도 - Google Patents
디뉴클레오티드 및 그의 용도 Download PDFInfo
- Publication number
- KR100606131B1 KR100606131B1 KR1019997007070A KR19997007070A KR100606131B1 KR 100606131 B1 KR100606131 B1 KR 100606131B1 KR 1019997007070 A KR1019997007070 A KR 1019997007070A KR 19997007070 A KR19997007070 A KR 19997007070A KR 100606131 B1 KR100606131 B1 KR 100606131B1
- Authority
- KR
- South Korea
- Prior art keywords
- uridine
- tetraphosphate
- pharmaceutically acceptable
- compound
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/797,472 | 1997-02-06 | ||
| US8/797,472 | 1997-02-06 | ||
| US08/797,472 US5900407A (en) | 1997-02-06 | 1997-02-06 | Method of treating dry eye disease with uridine triphosphates and related compounds |
| US8/798,508 | 1997-02-10 | ||
| US08/798,508 | 1997-02-10 | ||
| US08/798,508 US5837861A (en) | 1997-02-10 | 1997-02-10 | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
| PCT/US1998/002702 WO1998034942A2 (en) | 1997-02-06 | 1998-02-06 | Dinucleotides and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20000070807A KR20000070807A (ko) | 2000-11-25 |
| KR100606131B1 true KR100606131B1 (ko) | 2006-07-31 |
Family
ID=27121880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019997007070A Expired - Fee Related KR100606131B1 (ko) | 1997-02-06 | 1998-02-06 | 디뉴클레오티드 및 그의 용도 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6348589B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP0981534B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4531867B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100606131B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1262556C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE325129T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU738907C (cg-RX-API-DMAC7.html) |
| BR (1) | BR9807169A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2279963C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69834392T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0981534T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2264197T3 (cg-RX-API-DMAC7.html) |
| NO (1) | NO326718B1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ337225A (cg-RX-API-DMAC7.html) |
| PT (1) | PT981534E (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998034942A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6673779B2 (en) * | 1996-03-27 | 2004-01-06 | Inspire Pharmaceuticals, Inc. | Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues |
| US6319908B1 (en) | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
| US5763447C1 (en) | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
| EP0981534B1 (en) | 1997-02-06 | 2006-05-03 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their uses |
| US7078391B2 (en) | 1997-02-10 | 2006-07-18 | Inspire Pharmaceuticals, Inc. | Method of treating edematous retinal disorders |
| US7223744B2 (en) * | 1997-02-10 | 2007-05-29 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof |
| US6596725B2 (en) * | 1997-02-10 | 2003-07-22 | Inspire Pharmaceuticals, Inc. | Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema |
| US6818629B2 (en) * | 1997-02-10 | 2004-11-16 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate |
| US6462028B2 (en) | 1997-07-25 | 2002-10-08 | Inspire Pharmaceuticals, Inc. | Method of promoting cervical and vaginal secretions |
| TW593331B (en) | 1997-07-25 | 2004-06-21 | Inspire Pharmaceuticals Inc | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
| US6548658B2 (en) * | 1997-07-25 | 2003-04-15 | Inspire Pharmaceuticals, Inc. | Di-(uridine 5′)-tetraphosphate and salts thereof |
| US6872710B2 (en) * | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
| CA2295515C (en) * | 1997-07-25 | 2006-03-14 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof |
| BR9811612A (pt) * | 1997-08-29 | 2000-08-08 | Univ North Carolina | Uso de 5' -difosfato de uridina e similares para tratamento de doenças pulmonares |
| DE69905464T2 (de) * | 1998-05-22 | 2004-01-15 | Inspire Pharmaceuticals Inc | Therapeutische dinucleotide und deren derivate |
| EP1140967A1 (en) * | 1998-12-23 | 2001-10-10 | University Of North Carolina At Chapel Hill | Targeted gene transfer using g protein coupled receptors |
| KR20010114214A (ko) | 1999-02-26 | 2001-12-31 | 인스파이어 파마슈티컬스 인코퍼레이티드 | 우리딘, 아데닌 및 시티딘 디포스페이트 및 그의 유사체에의한 점막수화 촉진방법 |
| NZ516301A (en) * | 1999-06-30 | 2003-07-25 | Yamasa Corp | Dinucleotide crystals |
| AU6551800A (en) * | 1999-08-17 | 2001-03-13 | Adani, Alexander | Dinucleoside 5',5'-tetraphosphates as inhibitors of viral reverse transcriptasesand viruses |
| JP2003524636A (ja) * | 1999-12-22 | 2003-08-19 | インスパイアー ファーマシューティカルズ,インコーポレイティド | プリン性受容体アゴニストによる胃腸管の処置方法 |
| RU2161982C1 (ru) * | 2000-01-20 | 2001-01-20 | Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии" | Тетрапептид, стимулирующий функцию сетчатой оболочки глаза, фармакологическое средство на его основе и способ его применения |
| US6864243B1 (en) * | 2000-05-12 | 2005-03-08 | Inspire Pharmaceuticals, Inc. | Method for treating retinal degeneration with purinergic receptor agonists |
| AU2001260643B9 (en) | 2000-05-30 | 2006-10-19 | Merck Sharp & Dohme Corp. | Ectocornea extension promoters |
| US7115585B2 (en) * | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
| US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US6867199B2 (en) | 2000-08-21 | 2005-03-15 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapeutic use |
| US6555675B2 (en) * | 2000-08-21 | 2003-04-29 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists |
| US7132408B2 (en) * | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| JP2005502580A (ja) * | 2000-12-15 | 2005-01-27 | フアーマセツト・リミテツド | フラビウィルス感染治療用抗ウィルス薬 |
| US20040122223A1 (en) * | 2001-02-07 | 2004-06-24 | Davis Jeremy Martin | Non-natural nucleotides and dinucleotides |
| WO2003000056A1 (en) | 2001-06-25 | 2003-01-03 | Inspire Pharmaceuticals, Inc. | Joint lubrication with p2y purinergic receptor agonists |
| US20050009777A1 (en) * | 2001-07-25 | 2005-01-13 | Mack Stephen Robert | Non-natural carbon-linked nucleotides and dinucleotides |
| WO2003030892A1 (en) * | 2001-10-11 | 2003-04-17 | Alcon, Inc. | Methods for treating dry eye |
| MXPA04004215A (es) | 2001-11-06 | 2004-07-08 | Inspire Pharmaceuticals Inc | Metodo para el tratamiento o la prevencion de enfermedades inflamatorias. |
| US7084128B2 (en) | 2002-01-18 | 2006-08-01 | Inspire Pharmaceuticals, Inc. | Method for reducing intraocular pressure |
| MXPA05004121A (es) * | 2002-10-18 | 2006-02-17 | Molichem Medicines Inc | Metodos para tratar la enfermedad de ojo reseco con lantibioticos. |
| US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
| WO2005107787A1 (en) * | 2004-05-06 | 2005-11-17 | Molichem Medicines, Inc. | Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions |
| CA2565545A1 (en) * | 2004-05-06 | 2005-12-08 | Molichem Medicines, Inc. | Treatment of ocular diseases and disorders using lantibiotic compositions |
| GB0417886D0 (en) * | 2004-08-11 | 2004-09-15 | Univ Cardiff | Method and means for enhanced pulmonary delivery |
| GB0502250D0 (en) * | 2005-02-03 | 2005-03-09 | Ic Vec Ltd | Use |
| US7368439B2 (en) * | 2005-06-15 | 2008-05-06 | Bar - Ilan University | Dinucleoside poly(borano)phosphate derivatives and uses thereof |
| US7851456B2 (en) * | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
| EP2036567A3 (en) | 2005-12-06 | 2009-12-09 | P2-Science APS | Modulation of the P2Y2 receptor pathway |
| US20070249556A1 (en) * | 2006-04-21 | 2007-10-25 | Brubaker Kurt E | Method of treating inflammation |
| WO2008012949A1 (en) * | 2006-07-26 | 2008-01-31 | Yamasa Corporation | Process for producing di(pyrimidine nucleoside 5'-)polyphosphate |
| EP2049665A2 (en) * | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| WO2009049159A1 (en) | 2007-10-10 | 2009-04-16 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
| US8168597B2 (en) * | 2008-10-22 | 2012-05-01 | Inspire Pharmaceuticals, Inc. | Method for treating cystic fibrosis |
| US9067964B2 (en) | 2008-12-18 | 2015-06-30 | Oligomer Sciences Ab | Complex and method for enhancing nuclear delivery |
| US9011909B2 (en) | 2010-09-03 | 2015-04-21 | Wisconsin Pharmacal Company, Llc | Prebiotic suppositories |
| CA2810481C (en) * | 2010-09-10 | 2018-06-19 | Santen Pharmaceutical Co., Ltd. | Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof |
| EP2717855A4 (en) | 2011-06-07 | 2014-11-12 | Parion Sciences Inc | Methods of Treatment |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| MY169816A (en) | 2012-03-26 | 2019-05-16 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol |
| WO2013181232A2 (en) | 2012-05-29 | 2013-12-05 | Michael Ross Johnson | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases |
| RU2671976C2 (ru) | 2012-12-17 | 2018-11-08 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
| ES2674665T3 (es) | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
| HUE032891T2 (hu) | 2012-12-17 | 2017-11-28 | Parion Sciences Inc | Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére |
| CA2956163C (en) | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| ES2963057T3 (es) | 2015-03-09 | 2024-03-25 | Grace W R & Co | Forma cristalina de ribósido de nicotinamida |
| EP3297615A1 (en) * | 2015-05-20 | 2018-03-28 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for modulation polarization and activation of macrophages |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
| EP3919062A1 (en) | 2020-06-02 | 2021-12-08 | Institut Gustave-Roussy | Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom |
| US20230302031A1 (en) | 2020-06-02 | 2023-09-28 | Institut Gustave-Roussy | Modulators Of Purinergic Receptors and Related Immune Checkpoint For Treating Acute Respiratory Distress Syndrome |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996002554A1 (en) * | 1994-07-15 | 1996-02-01 | Gruppo Lepetit S.P.A. | Dinucleoside-5',5'-pyrophosphates |
| WO1996040059A1 (en) * | 1995-06-07 | 1996-12-19 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of lung disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4855304A (en) | 1985-01-10 | 1989-08-08 | Repligen Corporation | Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals |
| US5049550A (en) | 1987-11-05 | 1991-09-17 | Worcester Foundation For Experimental Biology | Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents |
| US5292498A (en) * | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
| US5837861A (en) * | 1997-02-10 | 1998-11-17 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
| US5681823A (en) | 1996-05-02 | 1997-10-28 | Prp Inc. | P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent |
| US5789391A (en) * | 1996-07-03 | 1998-08-04 | Inspire Pharmaceuticals, Inc. | Method of treating sinusitis with uridine triphosphates and related compounds |
| US5763447C1 (en) * | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
| AU4815197A (en) * | 1996-10-09 | 1998-05-05 | Pharmasset, Ltd. | Tetraphosphonate bicyclic trisanhydrides |
| EP0981534B1 (en) | 1997-02-06 | 2006-05-03 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their uses |
-
1998
- 1998-02-06 EP EP98907435A patent/EP0981534B1/en not_active Expired - Lifetime
- 1998-02-06 CA CA002279963A patent/CA2279963C/en not_active Expired - Fee Related
- 1998-02-06 NZ NZ337225A patent/NZ337225A/en not_active IP Right Cessation
- 1998-02-06 CN CNB988032597A patent/CN1262556C/zh not_active Expired - Fee Related
- 1998-02-06 AU AU63242/98A patent/AU738907C/en not_active Ceased
- 1998-02-06 ES ES98907435T patent/ES2264197T3/es not_active Expired - Lifetime
- 1998-02-06 DE DE69834392T patent/DE69834392T2/de not_active Expired - Lifetime
- 1998-02-06 JP JP53505598A patent/JP4531867B2/ja not_active Expired - Fee Related
- 1998-02-06 DK DK98907435T patent/DK0981534T3/da active
- 1998-02-06 AT AT98907435T patent/ATE325129T1/de active
- 1998-02-06 US US09/101,395 patent/US6348589B1/en not_active Expired - Lifetime
- 1998-02-06 WO PCT/US1998/002702 patent/WO1998034942A2/en not_active Ceased
- 1998-02-06 BR BR9807169-6A patent/BR9807169A/pt active Search and Examination
- 1998-02-06 KR KR1019997007070A patent/KR100606131B1/ko not_active Expired - Fee Related
- 1998-02-06 PT PT98907435T patent/PT981534E/pt unknown
-
1999
- 1999-08-04 NO NO19993776A patent/NO326718B1/no not_active IP Right Cessation
-
2001
- 2001-11-06 US US10/007,451 patent/US6977246B2/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996002554A1 (en) * | 1994-07-15 | 1996-02-01 | Gruppo Lepetit S.P.A. | Dinucleoside-5',5'-pyrophosphates |
| WO1996040059A1 (en) * | 1995-06-07 | 1996-12-19 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of lung disease |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998034942A2 (en) | 1998-08-13 |
| NO326718B1 (no) | 2009-02-02 |
| DK0981534T3 (da) | 2006-09-04 |
| ATE325129T1 (de) | 2006-06-15 |
| ES2264197T3 (es) | 2006-12-16 |
| AU738907C (en) | 2002-05-16 |
| US6348589B1 (en) | 2002-02-19 |
| CA2279963C (en) | 2008-04-22 |
| AU6324298A (en) | 1998-08-26 |
| NO993776D0 (no) | 1999-08-04 |
| EP0981534B1 (en) | 2006-05-03 |
| JP4531867B2 (ja) | 2010-08-25 |
| CN1262556C (zh) | 2006-07-05 |
| CA2279963A1 (en) | 1998-08-13 |
| JP2001526635A (ja) | 2001-12-18 |
| WO1998034942A3 (en) | 2000-01-06 |
| KR20000070807A (ko) | 2000-11-25 |
| PT981534E (pt) | 2006-09-29 |
| BR9807169A (pt) | 2000-06-06 |
| NO993776L (no) | 1999-10-06 |
| US6977246B2 (en) | 2005-12-20 |
| DE69834392D1 (de) | 2006-06-08 |
| CN1292795A (zh) | 2001-04-25 |
| DE69834392T2 (de) | 2007-02-08 |
| AU738907B2 (en) | 2001-09-27 |
| EP0981534A2 (en) | 2000-03-01 |
| NZ337225A (en) | 2002-03-28 |
| US20020082417A1 (en) | 2002-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU738907C (en) | Dinucleotides and their use | |
| US5837861A (en) | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency | |
| JP3723227B2 (ja) | ジ(ウリジン5’)−テトラホスフェート及びその塩の大規模生産のための方法 | |
| AU2003217863B2 (en) | Nucleotide mimics and their prodrugs | |
| EP0980377B1 (en) | Anti-viral pyrimidine nucleoside analogues | |
| JP4633927B2 (ja) | 治療用ジヌクレオチドおよび誘導体 | |
| EP1280813B1 (en) | Anti-viral pyrimidine nucleoside analogues | |
| NZ535246A (en) | 3'-prodrugs of 2'-deoxy-beta-L-nucleosides | |
| US7091334B2 (en) | Method for large-scale production of di(uridine 5′)-tetraphosphate and salts thereof | |
| US6555675B2 (en) | Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists | |
| US6867199B2 (en) | Dinucleoside polyphosphate compositions and their therapeutic use | |
| JP4879398B2 (ja) | グリセリルヌクレオチド、それらの製造法および使用 | |
| US7132410B2 (en) | Di(uridine 5′-)tetraphosphate and salts thereof | |
| MXPA99007236A (en) | Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency | |
| HK1033464A (en) | Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency | |
| MXPA99009965A (en) | Anti-viral pyrimidine nucleoside analogues | |
| MXPA99011769A (en) | Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE AMENDMENT REQUESTED 20041014 Effective date: 20051116 |
|
| PJ1301 | Trial decision |
St.27 status event code: A-3-3-V10-V15-crt-PJ1301 Decision date: 20051116 Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline amendment, Appeal Ground Text : 1999 7007070 Appeal request date: 20041014 Appellate body name: Patent Examination Board Decision authority category: Office appeal board Decision identifier: 2004102000058 |
|
| PS0901 | Examination by remand of revocation |
St.27 status event code: A-6-3-E10-E12-rex-PS0901 |
|
| S901 | Examination by remand of revocation | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| GRNO | Decision to grant (after opposition) | ||
| PS0701 | Decision of registration after remand of revocation |
St.27 status event code: A-3-4-F10-F13-rex-PS0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20131031 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20140627 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R14-asn-PN2301 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20160629 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 11 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20170721 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-5-5-R10-R17-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20170721 |